Federal Grant Award Summary

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $770,000 Project Grant to The Leland Stanford Junior University, effective April 1, 2026, through January 31, 2033, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative aims to advance understanding of cardiomyopathy through investigation of endothelial cell and cardiomyocyte crosstalk using an integrated multimodal approach. The project will deliver fundamental scientific research products, including mechanistic insights into how endothelial dysfunction contributes to cardiac dysfunction in both inherited cardiomyopathies (caused by genetic mutations) and acquired cardiomyopathies (resulting from chemotherapeutic exposure or other comorbidities).

The research outputs will be generated through Stanford's multidisciplinary methodology integrating human induced pluripotent stem cells (iPSCs), bioengineering tools, single-cell omics analysis, and animal cardiomyopathy models. The funded research is expected to produce peer-reviewed publications, characterization of molecular signaling mechanisms between endothelial and cardiac cells, identification of therapeutic targets, and translational insights applicable to cardiomyopathy prevention and treatment. This project directly supports the NHLBI's mission to advance basic, translational, and clinical research to reduce morbidity and mortality from cardiovascular diseases.